The impact of spike N501Y mutation on neutralizing activity and RBD binding of SARS-CoV-2 convalescent serum
Lu Lu(Fudan University), Kelvin Kai‐Wang To(Hong Kong Science and Technology Parks Corporation), David Christopher Lung(Ten Chen Hospital), Anthony Raymond Tam(University of Hong Kong), G. G. Siu(Hong Kong Polytechnic University), Lin‐Lei Chen(Queen Mary Hospital), Tak-Chuen Ip(Queen Mary Hospital), Hoi‐Wah Tsoi(University of Hong Kong), Haisu Yi(First Affiliated Hospital of Guangzhou Medical University), Ivan Fan‐Ngai Hung(Chinese University of Hong Kong), Vincent Chi‐Chung Cheng(Queen Mary Hospital), Yat-Sun Yau(Queen Elizabeth Hospital), Mike Yat Wah Kwan(Princess Margaret Hospital), Bobo Wing-Yee Mok(Chinese University of Hong Kong), Jonathan Daniel Ip(University of Hong Kong), Jian‐Piao Cai(University of Hong Kong), Wan-Mui Chan(University of Hong Kong), Kwok‐Yung Yuen(University of Hong Kong - Shenzhen Hospital), Rosana Wing‐Shan Poon(University of Hong Kong), Allen Wing‐Ho Chu(University of Hong Kong), Wing‐Kin To, Kwok Hung Chan(University of Hong Kong), Larry Lap-Yip Lee, Owen Tak‐Yin Tsang(Hospital Authority), Ruiqi Zhang(University of Hong Kong)
Cited by 44
Related Papers
A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster
|The Lancet|2020|9.6k
Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study
|The Lancet Infectious Diseases|2020|3.4k
Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan
|Emerging Microbes & Infections|2020|3.3k
Consistent Detection of 2019 Novel Coronavirus in Saliva
|Clinical Infectious Diseases|2020|2k
Coronaviruses — drug discovery and therapeutic options
|Nature Reviews Drug Discovery|2016|1.8k